Nicole M Valenzuela1, Jeffrey T McNamara, Elaine F Reed. 1. Department of Pathology and Laboratory Medicine, UCLA Immunogenetics Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: Antibody-mediated rejection (AMR) is emerging as the leading cause of chronic rejection and allograft failure. Traditionally, the mechanisms of graft injury mediated by donor-specific antibodies beyond complement activation were not well appreciated. However, an evolving paradigm of Fc-independent antibody functions, along with clinical recognition of C4d-negative AMR, has increased awareness of the action of antibodies leading to endothelial activation and dysfunction. RECENT FINDINGS: Herein, we address current clinical trends, including the signature of microvascular inflammation in biopsies of grafts undergoing AMR, the prevalence of antibodies to human leukocyte antigen class II DQ locus (HLA-DQ) and non-HLA targets, and the functional characterization of HLA immunoglobulin G (IgG) subclasses and complement-fixing capacity. We also discuss recent experimental evidence revealing new mechanisms of endothelial and smooth muscle cell activation by HLA antibodies, which may contribute to vascular inflammation and chronic rejection. Finally, we touch upon novel discoveries of the interplay between antibodies, the complement system, and CD4 T-cell-mediated alloimmunity. SUMMARY: The current literature suggests that, although complement-fixing antibodies may have some prognostic value for graft outcome, complement-independent mechanisms of graft injury are increasingly relevant. Therapeutic strategies, which target endothelial activation induced by antibodies may ameliorate vascular inflammation and mononuclear cell infiltration characteristic of AMR.
PURPOSE OF REVIEW: Antibody-mediated rejection (AMR) is emerging as the leading cause of chronic rejection and allograft failure. Traditionally, the mechanisms of graft injury mediated by donor-specific antibodies beyond complement activation were not well appreciated. However, an evolving paradigm of Fc-independent antibody functions, along with clinical recognition of C4d-negative AMR, has increased awareness of the action of antibodies leading to endothelial activation and dysfunction. RECENT FINDINGS: Herein, we address current clinical trends, including the signature of microvascular inflammation in biopsies of grafts undergoing AMR, the prevalence of antibodies to human leukocyte antigen class II DQ locus (HLA-DQ) and non-HLA targets, and the functional characterization of HLA immunoglobulin G (IgG) subclasses and complement-fixing capacity. We also discuss recent experimental evidence revealing new mechanisms of endothelial and smooth muscle cell activation by HLA antibodies, which may contribute to vascular inflammation and chronic rejection. Finally, we touch upon novel discoveries of the interplay between antibodies, the complement system, and CD4 T-cell-mediated alloimmunity. SUMMARY: The current literature suggests that, although complement-fixing antibodies may have some prognostic value for graft outcome, complement-independent mechanisms of graft injury are increasingly relevant. Therapeutic strategies, which target endothelial activation induced by antibodies may ameliorate vascular inflammation and mononuclear cell infiltration characteristic of AMR.
Authors: Marta Crespo; Alberto Torio; Virginia Mas; Dolores Redondo; Maria J Pérez-Sáez; Marisa Mir; Anna Faura; Rita Guerra; Olga Montes-Ares; Maria D Checa; Julio Pascual Journal: Transpl Immunol Date: 2013-07-29 Impact factor: 1.708
Authors: M Giral; Y Foucher; A Dufay; J P Duong Van Huyen; K Renaudin; A Moreau; A Philippe; B Hegner; R Dechend; H Heidecke; S Brouard; A Cesbron; S Castagnet; A Devys; J P Soulillou; D Dragun Journal: Am J Transplant Date: 2013-08-06 Impact factor: 8.086
Authors: M Taniguchi; L M Rebellato; J Cai; J Hopfield; K P Briley; C E Haisch; P G Catrou; P Bolin; K Parker; W T Kendrick; S A Kendrick; R C Harland; P I Terasaki Journal: Am J Transplant Date: 2013-08-13 Impact factor: 8.086
Authors: James H Lan; David Gjertson; Ying Zheng; Stephanie Clark; Elaine F Reed; Michael J Cecka Journal: Am J Transplant Date: 2018-05-09 Impact factor: 8.086